Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 9/20 | 0.44 |
| ▸ | CTSA | P10619 | 6/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29371834 | 1.00 | PTGER3 (0.44) | PTGER3CTSACNR2SLC22A12P2RY14 | |
| SCHEMBL688053 | 0.95 | PTGER3 (0.43) | PTGER3CTSACNR2SLC22A12 | |
| SCHEMBL688284 | 0.95 | PTGER3 (0.43) | PTGER3CTSACNR2SLC22A12 | |
| SCHEMBL687923 | 0.94 | PTGER3 (0.41) | PTGER3CTSACNR2SLC22A12 | |
| SCHEMBL686806 | 0.94 | PTGER3 (0.45) | PTGER3CTSACNR2P2RY14 | |
| SCHEMBL24868402 | 0.93 | PTGER3 (0.44) | PTGER3CNR2SLC22A12P2RY14 | |
| SCHEMBL688581 | 0.92 | PTGER3 (0.44) | PTGER3CNR2SLC22A12 | |
| SCHEMBL686663 | 0.92 | PTGER3 (0.44) | PTGER3CTSACNR2P2RY14 | |
| SCHEMBL686842 | 0.92 | PTGER3 (0.45) | PTGER3CTSACNR2SLC22A12 | |
| SCHEMBL686997 | 0.92 | PTGER3 (0.39) | PTGER3CTSACNR2SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1203766-B1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC (US) | 2012-02-29 | — | — | EP | claimed |
| US-20070060608-A1 | Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds | ENCYSIVE PHARMACEUTICALS INC. (US) | 2007-03-15 | — | — | US | claimed |
| US-6972296-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-06 | — | — | US | claimed |
| US-20040063955-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | claimed |
| EP-1203766-A2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-05-08 | — | — | EP | claimed |
| US-20230033021-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN INTEGRIN INHIBITOR | GLAS USA LLC | 2023-02-02 | — | — | US | disclosed |
| US-20230009902-A1 | TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORGINATING FROM THE ENDODERM | GLAS USA LLC | 2023-01-12 | — | — | US | disclosed |
| US-20210393811-A1 | Imaging Agents and Methods of Use | TEXAS HEART INSTITUTE | 2021-12-23 | — | — | US | disclosed |
| US-20200323772-A1 | TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR | BT BIDCO LLC | 2020-10-15 | — | — | US | disclosed |
| WO-2020072784-A1 | IMAGING AGENTS AND METHODS OF USE | TEXAS HEART INSTITUTE (US) | 2020-04-09 | — | — | WO | disclosed |
| EP-1203766-B1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC (US) | 2012-02-29 | — | — | EP | disclosed |
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| WO-2010008719-A2 | ORAL PHARMACEUTICAL FORMULATIONS OF VLA-4 ANTAGONISTS | SCHERING CORPORATION (US) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010008719-A2 | ORAL PHARMACEUTICAL FORMULATIONS OF VLA-4 ANTAGONISTS | SCHERING CORPORATION (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20070060608-A1 | Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds | ENCYSIVE PHARMACEUTICALS INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | BIEDIGER RONALD J | 2006-12-07 | — | — | US | disclosed |
| US-6972296-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-20040063955-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| JP-2003119181-A | CARBOXYLIC ACID DERIVATIVE INHIBITING BINDING OF INTEGRIN TO RECEPTOR | TEXAS BIOTECHNOLOGY CORP | 2003-04-23 | — | — | JP | disclosed |
| EP-1203766-A2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, ITGA1 | PTGER3 2942/4885CTSA 686/4885CNR2 2011/4885 |
| US-20230033021-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN INTEGRIN INHIBITOR | ITGAL, ITGB2, ITGB1 | PTGER3 450/4885CTSA 3023/4885CNR2 3122/4885 |
| US-20040063955-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, FN1 | PTGER3 2649/4885CTSA 471/4885CNR2 1897/4885 |
| US-20070060608-A1 | Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds | VCAM1, ITGB1, ICAM1 | PTGER3 2584/4885CTSA 960/4885CNR2 3169/4885 |
| US-20230009902-A1 | TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORGINATING FROM THE ENDODERM | ALPG, ALPP, FABP2 | PTGER3 1810/4885CTSA 2145/4885CNR2 2151/4885 |
| US-20210393811-A1 | Imaging Agents and Methods of Use | ITGA1, ITGA4, CD47 | PTGER3 1491/4885CTSA 2666/4885CNR2 1575/4885 |
| US-20200323772-A1 | TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR | LRBA, CD47, FABP2 | PTGER3 524/4885CTSA 894/4885CNR2 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.